Psoriasis Completed Phase 3 Trials for Infliximab (DB00065)

Also known as: PSORIASIS / Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00106834A Study of the Safety and Efficacy of Infliximab in Patients With PsoriasisTreatment
NCT00106847A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type PsoriasisTreatment
NCT00254982Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)Treatment
NCT00251641The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)Treatment
NCT00686686Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)Treatment
NCT00687401A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)Treatment
NCT00527072PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to EtanerceptTreatment
NCT01177800A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type PsoriasisTreatment